Skip to content

Adult Intracranial Malignant Hemangiopericytoma C1334558

Published: July 22, 2026Updated: August 20, 2026

A rare, aggressive tumor that develops from cells surrounding blood vessels inside the skull. More common in adults, it tends to recur after treatment. Management usually involves surgery and radiation therapy, requiring long-term monitoring.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Headache

!

Focal neurological deficit

Generalized symptoms

(oncologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Dizziness

(neurologic)

Seizures

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Radical Surgical Resection

Aggressive surgical removal of the intracranial hemangiopericytoma with wide margins when possible. Complete resection is challenging due to vascular nature and location.

surgical
3

Stereotactic Radiosurgery

Focused radiation delivery to tumor margins using precise targeting technology. Often used adjuvantly after surgery or for unresectable or recurrent lesions.

procedure

Additional treatment options

Fractionated Radiation Therapy

Conventional external beam radiation delivered in multiple fractions for tumors in sensitive locations or when radiosurgery is not appropriate.

procedure

Systemic Therapy

Targeted agents or chemotherapy used for metastatic or recurrent disease that cannot be controlled with local therapies alone.

medication

Long-term Imaging Follow-up

Extended surveillance with periodic imaging studies due to high recurrence rates of malignant hemangiopericytoma. Scans may include MRI and CT.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Adult Intracranial Malignant Hemangiopericytoma C1334558?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Adult Intracranial Malignant Hemangiopericytoma C1334558. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy